Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus trastuzumab and chemotherapy in operable HER2-positive breast cancer
2010-022902-41Phase 3Unknown
- Sponsor
- Roche
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Chemotherapy + trastuzumab + pertuzumab with Chemotherapy + trastuzumab + placebo (2 arms). Primary endpoint: Invasive disease-free survival. Status: unknown.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-022902-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022902-41.